DelveInsight’s, “T cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
T cell lymphoma Understanding
T cell lymphoma: Overview
T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.
T-cell lymphomas encompass a group of heterogeneous diseases accounting for less than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.
In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence T cell lymphoma R&D. The therapies under development are focused on novel approaches for T cell lymphoma.
T cell lymphoma Emerging Drugs Chapters
This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T cell lymphoma Emerging Drugs
- SGX-301: Soligenix
SGX301 is a photodynamic therapy using synthetically manufactured hypericin in an ointment combined with visible fluorescent light. Hypericin is one of the most photoactive compounds known – it is easily activated with relatively low energy light. This makes it ideal for photodynamic therapy because it can be activated with fluorescent light, instead of UV A or UV B light, which are associated with increased cancer risks.
Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.
- SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. In a Phase II study in the U.S. Intravenous darinaparsin demonstrated evidence of clinical activity in malignant lymphoma, and in particular peripheral T-cell lymphoma (PTCL). Darinaparsin was granted Orphan Drug Designation in the U.S. and Europe as a treatment of PTCL and Solasia intends to seek similar status in Japan.
It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.
Further product details are provided in the report……..
T cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on T cell lymphoma
There are approx. 100+ key companies which are developing the T cell lymphoma. The companies which have their T cell lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Soligenix.
- Phases
DelveInsight’s report covers around 120+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
T cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
T cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.
T cell lymphoma Report Insights
- T cell lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
T cell lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing T cell lymphoma drugs?
- How many T cell lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T cell lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Celgene
- CSPC ZhongQi Pharmaceutical Technology
- Jazz Pharmaceuticals
- Genor Biopharma
- Eisai
- Soligenix
- Elorac
- Shanghai YingLi Pharmaceutical
- ViGenCell
- Daiichi Sankyo
- Chia Tai Tianqing Pharmaceutical Group
- BeiGene
- Kura Oncology
- Solasia Pharma
- Innovent bilogics
- Nanjing Sanhome Pharmaceutical
- Rhizen Pharmaceuticals SA
- 4SC AG
- Precision Bioscience
- Millennium Pharmaceuticals, Inc.
- Innate Pharma
- ImmuneOncia Therapeutics
- HUYA Bioscience International
- CerRx, Inc.
- Shandong New Time Pharmaceutical Co., LTD
- Verastem, Inc.
- Janssen Research & Development
- Celleron Therapeutics
- CStone Pharmaceuticals
- Viridian Therapeutics
- Hebei Senlang Biotechnology Inc.
- Galderma
- Seagen
- Bioniz Therapeutics
- Almirall
- Dizal Pharmaceuticals
- Pfizer
- Hoffmann-La Roche
- Affimed GmbH
- Sorrento Therapeutics
- Merck Sharp & Dohme
- Eli Lilly and Company
- Bayer
- Genzyme
- Portola Pharmaceuticals
- Onyx Pharmaceuticals
- AstraZeneca
- Astex Therapeutics
- Yake Biotechnology Ltd.
- Aileron Therapeutics
- Akeso Pharmaceuticals, Inc.
- Viracta
- Otsuka Pharmaceutical
- VelosBio
- Trillium Therapeutics Inc.
- Mundipharma-EDO GmbH
- TG Therapeutics, Inc.
- PersonGen BioTherapeutics (Suzhou) Co
- Sorrento Therapeutics
- Oncotartis
- Myeloid Therapeutics
- Bio-Path Holdings, Inc.
- Legend Biotech
- Immune Cell
- Genzada Pharmaceuticals
- Gracell
- CRISPR Therapeutics
- Corvus Pharmaceuticals, Inc.
- Rafael Therapeutics
- Antengene Corporation
- Viridian Therapeutics
- iCell Gene Therapeutics
- Tessa Therapeutics
- Boryung Pharmaceutical Co., Ltd
- Bristol-Myers Squibb
- Antengene Corporation
- Amgen
- ADC Therapeutics S.A.
- Legend Biotech USA Inc
- VidacPharma
- Medc Biopharma
- Scopus Biopharma
- Almirall
- Brickell Bio
- AVM Biotechnology
- Autolus
- Applied Therapeutics
- TetraLogic Pharmaceuticals
- Moleculin Biotech
Key Products
- Lenalidomide
- Mitoxantrone Hydrochloride
- JZP-458
- GB226
- Denileukin diftitox
- SGX 301
- Naloxone Hydrochloride
- YY-20394
- VT-EBV-N
- Valemetostat Tosylate
- TQ-B3525
- TQ-B3101
- Tislelizumab
- Tipifarnib
- SP-02L
- SP-02
- Sintilimab
- SHC014748M
- SGN-35
- RP6530
- Resminostat
- Pembrolizumab
- PBCAR20
- Nivolumab
- MLN 9708
- Letermovir
- Lacutamab
- IPH4102
- IMC-001
- HBI-8000
- Fenretinide
- F520
- Duvelisib
- DS-3201
- Daratumumab
- CXD 101
- CS1001
- Cobomarsen
- CD7 CAR-T
- CD11301
- Brentuximab Vedotin
- BNZ132-1-40
- BNZ1
- AZD4205
- Azacytidine
- Avelumab
- Atezolizumab
- AFM13
- STI-3031
- MK-3475
- LY3039478
- Durvalumab
- Copanlisib
- Clofarabine
- Cerdulatinib (PRT062070)
- carfilzomib
- AZD5991
- ASTX660
- ALRN-6924
- AUTO4
- AK104
- Nanatinostat + Valganciclovir
- ASTX660
- ARGX-110
- VLS-101
- TTI-621
- Tinostamustine
- TGR-1202
- Temsirolimus
- Sofusa anti-PD1
- SEA-TGT
- OT-82
- MT-101
- L-Bcl-2 antisense oligonucleotide
- LB1901
- ICAR30 T cells
- GZ17-6.02
- GC027
- CTX130
- CPI-818
- CPI-613/Devimistat
- Cobomarsen
- CD4 CAR T cells
- CD30.CAR-T
- BR101801
- BMS-906024
- AZD4573
- ATG-010
- AMG 319
- ADCT-301
- LB1901
- CD7-CART
- VDA-1102
- MDC 2021
- MDC 2020
- CO-sTiRNA
- CD-7 UCART
- BNZ1
- BBI-3000
- AVM-0703
- Auto 5
- AT-104
- Lorlatinib
- CPX-351
- SHP-141
- WP1220
Table of Contents
Introduction
Executive Summary
T cell lymphoma: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
T cell lymphoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
- T cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T cell lymphoma Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
SGX-301: Soligenix
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
- Comparative Analysis
AFM13: Affimed
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
- Comparative Analysis
MT-101: Myeloid Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery
……continued
CONTACT DETAILS :
+44 203 500 2763
+1 62 825 80070
971 0503084105
The research report on the global Generic Oncology Drugs Market published by Fast Mr demonstrates the crucial aspects that are envisioned to shape the growth of the market in the upcoming years.
The market for Generic Oncology Drugs Market is proposed to reach at a remarkable value by the end of 2025.
The global Generic Oncology Drugs Market is anticipated to grow at a noteworthy CAGR over the forecast period i.e.
In the past years, the market has grown at an extensive rate and is projected to represent a lucrative growth over the coming years.The study aims to provide the analysis of market size & forecast analysis for 2019-2025, covering the major growth factors and issues, and also including the market trends & opportunities of the global Generic Oncology Drugs Market.
The market research report also focuses on the macro-economic indicators and the other prospects including market overview, industry development, market maturity, PESTLE Analysis, and value chain analysis which help the clients to understand the market.Access Exclusive Sample Report on Generic Oncology Drugs Market with Covid -19 Impact - https://www.fastmr.com/request-s/101Moreover, the research report segregates the market segments on the basis of geographies & countries.
Also, the global Generic Oncology Drugs Market includes the section of competitive landscape covering the company market share & market positioning, company profiling, industry news & developments etc.Key Segments Covered in the Global Generic Oncology Drugs Market:- Market Sizing Analysis for 2019-2025- Growth Drivers & Barriers, Market Trends, and Market Opportunities- Impact Analysis of Corona virus Disease (COVID-19)- Market Segment Trend and Forecast- Regional & Country Level Analysis- Market Overview, Porter’s Five Forces Analysis, Trade Analysis- Industry Development, Market Maturity, Value Chain Analysis- Market Analysis and Various Recommendations- Key Market Driving Factors- Competitive Landscape: Company Market Share & Market Positioning, Company Profiling, Recent Industry News.Regional Viewpoint:In terms of region, the global Generic Oncology Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
The Oral Biologics And Biosimilars Global Market Report 2020-30 by The Business Research Company describes and explains the global oral biologics and biosimilars market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030.
View Complete Report:https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market The oral biologics and biosimilars market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success.
Oral Biologics And Biosimilars Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant.
The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens.
The Business Research Company’s latest report Oral Biologics and Biosimilars Global Market Report 2020 covers Oral Biologics and Biosimilars market drivers, Oral Biologics and Biosimilars market trends, Oral Biologics and Biosimilars market segments, Oral Biologics and Biosimilars market growth rate, Oral Biologics and Biosimilars market major players, and Oral Biologics and Biosimilars market size.
The report provides in-depth analysis of the impact of COVID-19 on the Oral Biologics and Biosimilars industry, along with revised market numbers due to the effects of the coronavirus.
View Complete Report:https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market Oral Biologics and Biosimilars Global Market Report 2020 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.
The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market.
The chapter also covers markets which have been positively affected by the pandemic.Request for the sample now:https://www.thebusinessresearchcompany.com/sample.aspx?id=3361=smpThe global oral biologics and biosimilars market reached a value of nearly $3,076.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 6.5% since 2015, and is expected to grow at a CAGR of 17.1% to nearly $5,787.9 million by 2023.
Also, the market is expected to growth to $8,687.7 million in 2025 at a CAGR of 22.5% and to $23,585.5 million in 2030 at a CAGR of 22.1%.The report covers the Oral Biologics and Biosimilars market’s segments- 1) By Therapeutic Mechanism: Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (Insulin, Growth Hormone, Parathyroid Hormone) Modulators, Immunostimulants, Others2) By Disease: Diabetes, Arthritis & Chron`S Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online PharmaciesTake a look at our exciting year-end deals on ALL reports!
The global ”cell lysis market” size is projected to grow at an excellent pace owing to the increasing prevalence of cancer worldwide, states Fortune Business Insights™ in its report, titled “Cell Lysis Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Cell Type (Mammalian Cells, Plant Cells, Bacterial Cells, Others (Yeast/Algae/Fungi)), By Application (Protein Isolation, Cell Organelle Isolation, Nucleic Acid Isolation, Others), By End-User (Academics & Research Institutes, Hospitals & Diagnostic Labs, Pharmaceutical & Biotechnology Companies) and Regional Forecast, 2020-2027”.According to the International Agency for Research on Cancer (IARC) under the World Health Organization (WHO), in 2018, the global burden of cancer grew to 18.1 million new cases and 9.6 million deaths.
During cancer treatment, cancer cells break down and die and release various substances into the patient’s bloodstream.
If these substances are released rapidly, the kidneys are unable to remove them out of the body, leading to cell lysis, which can have toxic effects on the body such as seizures, arrhythmias, and multi-organ failure.
To prevent such adverse events, intense research is being undertaken by academic institutions, government bodies, and private research organizations to develop cell lysis methods that can control the death rate of cancer cells.
Controlled release of toxic substances from these cells will enable the body’s natural mechanisms to effectively eject these materials fromthe body and restore the health of the patient.Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cell-lysis-market-103348List of Key Players Profiled in the Cell Lysis Market Report:Hoffmann-La Roche LtdCell Signaling Technology, Inc.Bio-Rad Laboratories, Inc.QIAGENBeckman Coulter, Inc.BDAn Overview of the Impact of COVID-19 on this Market:The emergence of COVID-19 has brought the world to a standstill.
We understand that this health crisis has brought an unprecedented impact on businesses across industries.
Global rhabdoid tumor treatment market is expected to gain market growth in the forecast period of 2021 to 2028.
Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.10% in the above mentioned forecast period.Rhabdoid tumor is defined as aggressive pediatric soft tissue sarcoma, which occurs in the kidney, the liver, the peripheral nerves, and all miscellaneous soft-parts throughout the body.
This tumor mostly occurs in infants and young children.
It sometimes grows in brain where it is known as atypical teratoid rhabdoid tumor (ATRT).
Rhabdoid tumor is also known as malignant rhabdoid tumor or rhabdoid sarcoma.Rise in the prevalence of disease, growing government initiatives, advancement in treatment options, genetic counselling, growing focus of major pharmaceutical companies towards novel treatment therapies and rising awareness are the factors that will expand the global rhabdoid tumor treatment market.Request Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rhabdoid-tumor-treatment-market Rising R activities and clinical trials will provide beneficial opportunities for the global rhabdoid tumor treatment market in the forecast period of 2021-2028.High cost of treatment, risk factors associated with the disease, and side effects of therapies are the factors that will hamper the market growth and will further challenge the global rhabdoid tumor treatment market in the forecast period mentioned above.Global Rhabdoid Tumor Treatment Market Country Level AnalysisGlobal rhabdoid tumor treatment market is analyzed and market size information is provided by the country, treatment, molecule type, route of administration, end-users and distribution channel as referenced above.The countries covered in the global rhabdoid tumor treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.Request for TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-rhabdoid-tumor-treatment-market Patient Epidemiology AnalysisGlobal rhabdoid tumor treatment market also provides you with detailed market analysis for patient analysis, prognosis, and cures.
Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.Competitive Landscape and Global Rhabdoid Tumor Treatment Market Share AnalysisGlobal rhabdoid tumor treatment market competitive landscape provides details by competitor.
Demand for Hepatitis C Treatment Expected to Remain High in North America during 2016-2024According to a recent study conducted by RRI, the global market forhepatitis C treatment is expected to expand at a CAGR of over 13% during the forecast period (2016-2024).
By the end of 2016, market is anticipated to stand at US$ 26.6 and is estimated to surpass US$ 71 Billion by 2024.Factors such as higher per capita healthcare expenditure worldwide and growing prevalence of hepatitis C infections in countries such as U.S. and Canada is expected to drive the global market for global hepatitis C treatment during the forecast period.
On the other hand, expensive drugs for hepatitis C treatment and lack of awareness about hepatitis C infection amongst the people in developing regions across the globe may inhibit the growth of the market during the forecast period.Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114958/Hepatitis-C-Treatment-Market On the basis of drugs, the global market for hepatitis C treatment has been segmented into HCV NS5A inhibitors, HCV protease inhibitors, interferon & antiviral, HCV polymerase inhibitors, and combination therapy.
The segment is expected to expand at a CAGR of over 13% during 2016-2024.On the basis distribution channel, the market has been segmented into online pharmacies, hospital pharmacies and retail pharmacies.
Hospital pharmacy is expected to be the most dominant segment during the forecast period.
The growth of the segment is due to ample stock of hepatitis C treatment drugs with added discount offered by online drug pharmacies.Request Report Discount: https://www.researchreportinsights.com/report/discount/110114958/Hepatitis-C-Treatment-Market On the basis of region, North America is expected to be the leading market for hepatitis C treatment, estimated to account for 45% share by the end of 2016.
